Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluomizin in bacterial vaginosis
NCT01125410Phase 3Completed
- Sponsor
- Medinova AG
- Start
- Jan 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial of dequalinium in bacterial vaginosis (BV) (2 arms), sponsored by Medinova AG. Primary endpoint: Clinical cure rate at 4 weeks. Started Jan 2007; status: completed.
02
Drugs
dequalinium
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT01125410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125410.